Skip to content

Strongbridge Biopharma plc

Delisted

CIK 1634432fmd_1E7GH46GBCT8ZZQ6ZVDH0Z5H8RManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2013 to Jun 30, 2021, 28 periods

Latest annual · FY2020

Millions
Total revenues
31
Gross profit
6
Operating income
(43)
Net income
(45)
Free cash flow
(38)

Latest quarter · Q2 FY2021

Millions
Total revenues
10
Operating income
(13)
Net income
(13)
Free cash flow
(10)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2017 to FY2020
+63.4%
Revenue, 5 yearsFY2015 to FY2020
n/m
Net income, 5 yearsFY2015 to FY2020
n/m

Strongbridge Biopharma plc financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2020FY2019ChangeSource
Revenue$30.7 million$21.7 million+41.5%10-K 2021-03-03 · proof
Operating income-$43.2 million-$67.1 million10-K 2021-03-03 · proof
Net income-$45.1 million-$49.5 million10-K 2021-03-03 · proof
Cash from operating activities-$38.1 million-$44.8 million10-K 2021-03-03 · proof
Free cash flow-$38.1 million-$44.9 million10-K 2021-03-03 · proof
Total assets$121.1 million$117.6 million+2.9%10-K 2021-03-03 · proof
Total liabilities$55.5 million$45.4 million+22.1%10-K 2021-03-03 · proof
Cash and cash equivalents$87.5 million$57 million+53.5%10-K 2021-03-03 · proof
What was Strongbridge Biopharma plc's revenue in fiscal 2020?
Strongbridge Biopharma plc reported revenue of $30.7 million for fiscal 2020 (the year ended Dec 31, 2020), against $21.7 million the year before (+41.5%). Source: the 10-K filed with the SEC on Mar 3, 2021. SEC
What was Strongbridge Biopharma plc's operating income in fiscal 2020?
Strongbridge Biopharma plc reported operating income of -$43.2 million for fiscal 2020 (the year ended Dec 31, 2020), against -$67.1 million the year before. Source: the 10-K filed with the SEC on Mar 3, 2021. SEC
What was Strongbridge Biopharma plc's net income in fiscal 2020?
Strongbridge Biopharma plc reported net income of -$45.1 million for fiscal 2020 (the year ended Dec 31, 2020), against -$49.5 million the year before. Source: the 10-K filed with the SEC on Mar 3, 2021. SEC
What was Strongbridge Biopharma plc's cash from operating activities in fiscal 2020?
Strongbridge Biopharma plc reported cash from operating activities of -$38.1 million for fiscal 2020 (the year ended Dec 31, 2020), against -$44.8 million the year before. Source: the 10-K filed with the SEC on Mar 3, 2021. SEC
What was Strongbridge Biopharma plc's free cash flow in fiscal 2020?
Strongbridge Biopharma plc reported free cash flow of -$38.1 million for fiscal 2020 (the year ended Dec 31, 2020), against -$44.9 million the year before. Source: the 10-K filed with the SEC on Mar 3, 2021. SEC
What are Strongbridge Biopharma plc's total assets?
As of Dec 31, 2020, Strongbridge Biopharma plc reported total assets of $121.1 million, against $117.6 million a year earlier (+2.9%). Source: the 10-K filed with the SEC on Mar 3, 2021. SEC
What are Strongbridge Biopharma plc's total liabilities?
As of Dec 31, 2020, Strongbridge Biopharma plc reported total liabilities of $55.5 million, against $45.4 million a year earlier (+22.1%). Source: the 10-K filed with the SEC on Mar 3, 2021. SEC
What are Strongbridge Biopharma plc's cash and cash equivalents?
As of Dec 31, 2020, Strongbridge Biopharma plc reported cash and cash equivalents of $87.5 million, against $57 million a year earlier (+53.5%). Source: the 10-K filed with the SEC on Mar 3, 2021. SEC

Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1634432&period_type=annual&limit=5"

Information only, not investment advice.